economictimes.indiatimes.com
The first batch of Covid-19 vaccines that were granted emergency approvals in 2020 and rolled out for immunisation in 2021 have not worked very well in providing long-term protection against newer variants and the world is waiting for newer jabs such as Novavax’s protein vaccine, its CEO Stanley Erck said.Novavax’s protein-based vaccine was approved for emergency use by the US Food and Drug Administration (USFDA) last month. The company has a research and manufacturing alliance with Pune-based S…
over 3 years ago